{"pressReleaseArticle":{"contentWrapper":{"title":"Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology","intro":"

Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.

","publishDateTime":"01/04/2014 00:00:00","publishDate":"01 April 2014","forInvestorsAndMediaOnlyText":"","shortDescription":"Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.","image":null,"downloadLink":null,"tags":[]},"components":[{"type":"rich-text","text":"

Issued: London UK

\n
\n
\n

Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncologyi. The study, known as PISCES, showed more patients expressed a preference for continuing treatment with Votrient® (pazopanib) than Sutent® (sunitinib). The objective of PISCES was to investigate patient-reported treatment preference and certain health-related quality of life outcomes for patients with locally advanced and/or metastatic renal cell carcinoma (aRCC or mRCC) who received no prior systemic therapy.

\n

The results showed that 70% (95%* CI, 60.9–78.4) of patients expressed a preference for pazopanib compared to 22% (95%* CI, 14.7–30.6) expressing a preference for sunitinib, as assessed by a questionnaire. This equates to a statistically significant difference of 49% (95%* CI, 34.7 - 63.8, p<0.001). Eight percent of patients expressed no preference. The PISCES study was not designed to measure or compare the clinical efficacy of either pazopanib or sunitinib.

\n

One of the secondary endpoints in this study was assessing the reasons for patient preference. The most commonly cited reasons for preferring pazopanib were “better quality of life” and “less fatigue”. In patients preferring sunitinib the most common reasons were “less diarrhoea” and “better quality of life”. 

\n

Faisal Mehmud, Head of US Oncology Medical Affairs, GSK, said: “There are now a number of therapies for advanced kidney cancer and as a result clinicians are striving to understand which medicines may be suitable for different patients. We hope that the results of the PISCES study will provide additional insights from the patient’s perspective into the treatment options available and further inform clinical practice.”

\n

Study design

\n

PISCES (PazopanIb versus Sunitinib patient preferenCE Study in treatment-naïve metastatic renal cell carcinoma) was a randomised, double-blind, multicentre, phase IIIb crossover study of 169 patients. The primary objective of this study was to assess how the tolerability and safety differences between GSK’s Votrient (pazopanib) versus Sutent (sunitinib) translate into patient preference, as determined by the patient’s stated preference for which drug they chose to continue treatment at the end of the study. Supplementary information was collected on the reasons for patient preference, fatigue and health-related quality of life, dose modifications and time to dose modification, and safety and tolerability.

\n

Adverse events (AEs) in PISCES

\n

The most common AEs (≥ 10% of patients, all grades) in this study for pazopanib compared to sunitinib, respectively, included: diarrhoea (42% vs. 32%), nausea (33% vs. 30%), decreased appetite (20% vs. 19%), vomiting (14% vs. 16%), dyspepsia (upset stomach) (10% vs. 16%), dysgeusia (taste alteration) (16% vs. 27%), mucositis (inflammation of the lining of the digestive tract) (16% vs. 22%), hand-foot syndrome (16% vs. 26%), hair colour changes (17% vs. 14%), hypertension (23% vs. 26%), asthenia (lack of energy) (16% vs. 24%), fatigue (29% vs. 30%), headache (14% vs. 11%), and abdominal pain (13% vs. 11%).

\n

Two fatal serious AEs (SAEs) were reported on pazopanib (respiratory failure and peritonitis) and two fatal SAEs were reported on sunitinib (dyspnoea and worsening of general condition). None of these fatal SAEs were considered treatment related. In addition, three patient deaths during the study occurred due to progressive disease (one patient receiving pazopanib and two patients on sunitinib).

\n

* Primary analysis data based on 90% CIs, for which the study was originally powered, are also included in the manuscript.

\n

About Votrient (pazopanib)

\n

Votrient was first approved by the US Food and Drug Administration for the treatment of patients with advanced renal cell carcinoma in October 2009 and received conditional marketing authorisation in the EU in June 2010. Votrient is now fully approved in the EU and in more than 85 countries.

\n

Severe and fatal hepatotoxicity has been observed in clinical trials with Votrient. Hepatic function should be monitored and dosing interrupted, reduced, or discontinued as recommended. Other potentially serious adverse reactions with Votrient include QT prolongations and torsades de pointes, cardiac dysfunction, haemorrhagic events, arterial and venous thrombotic events, thrombotic microangiopathy, gastrointestinal perforation and fistula, reversible posterior leukoencephalopathy syndrome, hypertension, wound healing, hypothyroidism, proteinuria, infection, increased toxicity with other cancer therapies, increased toxicity in developing organs (paediatric patients) and foetal harm.

\n

For further Important Safety Information about Votrient, in addition to approved uses, please visit:

\n

US Prescribing Information, BOXED WARNING, and Medication Guide: us.gsk.com/products/assets/us_votrient.pdf

\n

EU Summary of Product Characteristics:  www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf

\n

Votrient is a registered trademark of the GSK group of companies.

\n

Sutent is a registered trademark of C.P. Pharmaceuticals International C.V. (composed of Pfizer Manufacturing LLC and Pfizer Production LLC).

\n

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

\n

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.

\n


References

\n

i       Escudier B, Porta C, Bono P, et al. Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. J Clin Oncol published online at www.jco.org on March 31, 2014; DOI:10.1200/JCO.2013.50.8267

\n
\n
\n

 

","useGreyBackground":false,"fullWidth":false}]},"id":7838,"docCheckLogout":null,"pageType":"pressReleasePage","languageCode":"en-GB","theme":"light","breadcrumb":{"ariaLabel":"Breadcrumb","links":[{"text":"Home","href":"/en-gb/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Press releases","href":"/en-gb/media/press-releases/","openInNewWindowText":null},{"text":"Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology","href":"/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/","openInNewWindowText":null}]},"pageName":"Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology","topNav":{"homeLink":{"text":"GSK Homepage","href":"/en-gb/","openInNewWindowText":null},"topBar":{"currentLocation":{"isGlobal":true,"text":"Global"},"languageSelector":{"currentLanguage":null,"currentLanguageMobile":null,"selectableLanguages":[]},"darkModeSwitch":{"text":"Dark mode","tooltipText":"

Switch to dark mode to head towards a more sustainable world together. More info

"},"globalSiteLink":null,"locationSelector":{"text":"Change location","href":"/en-gb/locations/","openInNewWindowText":null},"healthCareLink":{"text":"Healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"contactUs":{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},"search":"Search","backToMain":"Back to main","menu":"Menu","closeMenu":"Close menu","animationsToggleModel":{"enable":true,"activeText":"Pause video","inactiveText":"Play video"}},"nodes":[{"tooltip":null,"hasBorderRight":true,"title":"Behind the Science magazine","url":"/en-gb/behind-the-science-magazine/","nodes":[],"isActive":false,"promos":[]},{"tooltip":null,"hasBorderRight":false,"title":"Company","url":"/en-gb/company/","nodes":[{"title":"Purpose, strategy and culture","url":"/en-gb/company/purpose-strategy-and-culture/","nodes":[],"isActive":false},{"title":"GSK at a glance","url":"/en-gb/company/gsk-at-a-glance/","nodes":[],"isActive":false},{"title":"History and heritage","url":"/en-gb/company/history-and-heritage/","nodes":[],"isActive":false},{"title":"Board of Directors and Executive Committee","url":"/en-gb/company/board-of-directors-and-leadership-team/","nodes":[],"isActive":false},{"title":"Board information","url":"/en-gb/company/board-information/","nodes":[],"isActive":false},{"title":"Governance","url":"/en-gb/company/governance/","nodes":[{"title":"Committees","url":"/en-gb/company/governance/committees/","nodes":[],"isActive":false},{"title":"Shareholders","url":"/en-gb/company/governance/shareholders/","nodes":[],"isActive":false},{"title":"Sarbanes-Oxley Act 2002","url":"/en-gb/company/governance/sarbanes-oxley-act-2002/","nodes":[],"isActive":false},{"title":"Compliance","url":"/en-gb/company/governance/compliance/","nodes":[],"isActive":false}],"isActive":false},{"title":"Policy positions","url":"/en-gb/company/policy-positions/","nodes":[],"isActive":false},{"title":"Codes, standards and reports","url":"/en-gb/company/codes-standards-and-reports/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Our purpose, strategy and culture","image":{"src":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=100&v=1dba2ec0bc1e680&hmac=13d78c5b371b5e09f560d958dfb6a3b8cb27a35b1578669ba061acc1b12273dd","alt":"GSK Tech Human Image","darkModeSrc":"/media/vvwddvsg/gsk_tech_human_image_6k.jpg?rxy=0.56833333333333336,0.30177514792899407&width=329&height=185&format=webp&quality=50&v=1dba2ec0bc1e680&hmac=7971e77f08fa2cbbfcb2e6dff5010e3d9c37f8561060dfbcdc7ec38ac7e5f314","fileSize":""},"link":{"text":"FEATURED SECTION","href":"/en-gb/company/purpose-strategy-and-culture/","openInNewWindowText":null}},{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0&hmac=9e8e9da5bd3ca0619cfd47c6274f5ecbae61a5b73808bbd57b4fdffa469f2037","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0&hmac=25f6331ff89b8ea1f896e23e1cc935cee241b346efb1b08bd5aa5b5aa0d4e09c","fileSize":""},"link":{"text":"FEATURED SECTION","href":"/en-gb/careers/outstanding-people/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Innovation","url":"/en-gb/innovation/","nodes":[{"title":"Therapeutic areas","url":"/en-gb/innovation/therapeutic-areas/","nodes":[{"title":"Respiratory, immunology and inflammation","url":"/en-gb/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/","nodes":[],"isActive":false},{"title":"Oncology","url":"/en-gb/innovation/therapeutic-areas/oncology/","nodes":[],"isActive":false},{"title":"HIV","url":"/en-gb/innovation/therapeutic-areas/hiv/","nodes":[],"isActive":false},{"title":"Infectious diseases","url":"/en-gb/innovation/therapeutic-areas/infectious-diseases/","nodes":[],"isActive":false}],"isActive":false},{"title":"Our leading scientists","url":"/en-gb/innovation/our-leading-scientists/","nodes":[{"title":"Dr Tony Wood","url":"/en-gb/innovation/our-leading-scientists/tony-wood/","nodes":[],"isActive":false},{"title":"Dr Sabine Luik","url":"/en-gb/innovation/our-leading-scientists/sabine-luik/","nodes":[],"isActive":false},{"title":"Dr Hesham Ahmed Abdullah","url":"/en-gb/innovation/our-leading-scientists/hesham-abdullah/","nodes":[],"isActive":false},{"title":"Dr Kaivan Khavandi","url":"/en-gb/innovation/our-leading-scientists/kaivan-khavandi/","nodes":[],"isActive":false},{"title":"Dr Christopher Austin","url":"/en-gb/innovation/our-leading-scientists/dr-christopher-austin/","nodes":[],"isActive":false},{"title":"Charlotte Allerton","url":"/en-gb/innovation/our-leading-scientists/charlotte-allerton/","nodes":[],"isActive":false},{"title":"Dr Sanjay Gurunathan","url":"/en-gb/innovation/our-leading-scientists/dr-sanjay-gurunathan/","nodes":[],"isActive":false}],"isActive":false},{"title":"Research and development approach","url":"/en-gb/innovation/research-and-development-approach/","nodes":[],"isActive":false},{"title":"Pipeline","url":"/en-gb/innovation/pipeline/","nodes":[],"isActive":false},{"title":"Tech","url":"/en-gb/innovation/technologies/","nodes":[{"title":"Post-quantum cryptography","url":"/en-gb/innovation/technologies/post-quantum-cryptography/","nodes":[],"isActive":false}],"isActive":false},{"title":"Clinical trials at GSK","url":"/en-gb/innovation/trials/","nodes":[{"title":"Provision of unapproved medicines for unmet medical needs","url":"/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/","nodes":[],"isActive":false},{"title":"Data transparency","url":"/en-gb/innovation/trials/data-transparency/","nodes":[],"isActive":false},{"title":"Representative clinical studies","url":"/en-gb/innovation/trials/representative-clinical-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"Partnering with GSK","url":"/en-gb/innovation/partnerships/","nodes":[{"title":"Supported studies","url":"/en-gb/innovation/partnerships/supported-studies/","nodes":[],"isActive":false}],"isActive":false},{"title":"R&D locations","url":"/en-gb/innovation/rd-locations/","nodes":[{"title":"Flagship R&D centre in Cambridge, UK","url":"/en-gb/innovation/rd-locations/flagship-rd-centre-in-cambridge-uk/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Behind the science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130&hmac=c3e21840aa4184183d7a56b6b9e51c276f4c0cfa99faddf0b2e96abade984999","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130&hmac=1ee1d1cba0cbe920daab92982b410dfd5be6b812ffb18d46bc5a1b15dc8ea9e4","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Our leading scientists","image":{"src":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=100&v=1dc651e856734f0&hmac=89240d0220a7a43a3ae9394fb29afbab3cb4192dc9283cc81575d646ff2c2d97","alt":"Tony Wood","darkModeSrc":"/media/45khexa4/tony-16x9.jpg?rxy=0.5733215608441357,0.39891812701082546&width=329&height=185&format=webp&quality=50&v=1dc651e856734f0&hmac=aa2617bc227baad2755a0fb9ad1fbe695d7cd6bbae99b54a174e6ece08ac6f3f","fileSize":""},"link":{"text":"Featured section","href":"/en-gb/innovation/our-leading-scientists/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Products","url":"/en-gb/products/","nodes":[{"title":"Product areas","url":"/en-gb/products/our-product-areas/","nodes":[],"isActive":false},{"title":"Products A-Z","url":"/en-gb/products/products-a-z/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Innovation","image":{"src":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe22d650&hmac=7e7c4f7e55d1c5f8195a127fe9f281066fa29131749b341d38ddb0d073a8c08e","alt":"Lab technician leaning against wall","darkModeSrc":"/media/jxkd3fld/web03-header-stvg_2_2022_port_5_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe22d650&hmac=a094b899394c4bc9edc97886a222232920b438f99f396aadeb7e3b2848f7ee89","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/","openInNewWindowText":null}},{"text":"GSKPro for healthcare professionals ","image":{"src":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe35c210&hmac=2075d37c23b475f2bc9ac77a07adcafcd381777fce6f7d574009e72fff69ff1f","alt":"Two scientists on orange background","darkModeSrc":"/media/xpibjmpq/navthumb_stvg_03_2022_port_32_eagle_orange-1.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe35c210&hmac=e50f7e49e96007544857017de5b32764327c6f3fd6d677c14972001d3b9771c4","fileSize":""},"link":{"text":"FEATURED WEBSITE","href":"https://gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"}}]},{"tooltip":null,"hasBorderRight":true,"title":"Responsibility","url":"/en-gb/responsibility/","nodes":[{"title":"Access","url":"/en-gb/responsibility/access/","nodes":[],"isActive":false},{"title":"Global health and health security","url":"/en-gb/responsibility/global-health-and-health-security/","nodes":[{"title":"Global health","url":"/en-gb/responsibility/global-health-and-health-security/global-health/","nodes":[],"isActive":false},{"title":"Health security","url":"/en-gb/responsibility/global-health-and-health-security/health-security/","nodes":[],"isActive":false},{"title":"Using our science for global health","url":"/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/","nodes":[],"isActive":false},{"title":"Africa Open Lab","url":"/en-gb/responsibility/global-health-and-health-security/africa-open-lab/","nodes":[],"isActive":false}],"isActive":false},{"title":"Environment","url":"/en-gb/responsibility/environment/","nodes":[{"title":"Climate","url":"/en-gb/responsibility/environment/climate/","nodes":[],"isActive":false},{"title":"Freshwater","url":"/en-gb/responsibility/environment/freshwater/","nodes":[],"isActive":false},{"title":"Land","url":"/en-gb/responsibility/environment/land/","nodes":[],"isActive":false},{"title":"Oceans","url":"/en-gb/responsibility/environment/oceans/","nodes":[],"isActive":false},{"title":"Materials and waste","url":"/en-gb/responsibility/environment/materials-and-waste/","nodes":[],"isActive":false},{"title":"Health system sustainability","url":"/en-gb/responsibility/environment/health-system-sustainability/","nodes":[],"isActive":false}],"isActive":false},{"title":"Inclusion","url":"/en-gb/responsibility/inclusion/","nodes":[],"isActive":false},{"title":"Ethical standards","url":"/en-gb/responsibility/ethical-standards/","nodes":[{"title":"Working with third parties","url":"/en-gb/responsibility/ethical-standards/working-with-third-parties/","nodes":[],"isActive":false},{"title":"Public policy and patient advocacy","url":"/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/","nodes":[],"isActive":false},{"title":"Human rights","url":"/en-gb/responsibility/ethical-standards/human-rights/","nodes":[],"isActive":false},{"title":"Use of animals","url":"/en-gb/responsibility/ethical-standards/use-of-animals/","nodes":[],"isActive":false},{"title":"Engaging with healthcare professionals","url":"/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/","nodes":[],"isActive":false}],"isActive":false},{"title":"Product governance","url":"/en-gb/responsibility/product-governance/","nodes":[],"isActive":false},{"title":"Grants and donations","url":"/en-gb/responsibility/grants-and-donations/","nodes":[],"isActive":false},{"title":"Charitable investments ","url":"/en-gb/responsibility/charitable-investments/","nodes":[],"isActive":false},{"title":"Responsibility reports","url":"/en-gb/responsibility/responsibility-reports/","nodes":[{"title":"Reports archive","url":"/en-gb/responsibility/responsibility-reports/responsibility-reports-archive/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030&hmac=12ac7ded8bd7ab6e4665214fcc035ed44c079abcb2fbda20ea2220be73c1f12e","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030&hmac=a50405e6d858c131f8bc642c26ae3a9fb06154803458a748320a0ff3ec9c7e2f","fileSize":""},"link":{"text":"FEATURED SECTION","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}},{"text":"Our policy positions","image":{"src":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebbe9b61b0&hmac=9e323e7d55541fa849cbe984c44f8a60da1e99fe2119d3c3fb9efb2dda7b58a8","alt":"GSK orange texture","darkModeSrc":"/media/110ltmz5/gsk_texture_fluid_03_a_cmyk_web-size_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebbe9b61b0&hmac=322065363b28083d211d5e68d0cffdbb01a506045f8e286c0284e908ea0a5805","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/company/policy-positions/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Investors","url":"/en-gb/investors/","nodes":[{"title":"Why invest in GSK?","url":"/en-gb/investors/why-invest-in-gsk/","nodes":[],"isActive":false},{"title":"Quarterly results","url":"/en-gb/investors/quarterly-results/","nodes":[],"isActive":false},{"title":"Financial reports","url":"/en-gb/investors/financial-reports/","nodes":[{"title":"Annual Report 2025","url":"/en-gb/investors/financial-reports/annual-report-2025/","nodes":[],"isActive":false},{"title":"Corporate reports archive","url":"/en-gb/investors/financial-reports/corporate-reports-archive/","nodes":[],"isActive":false}],"isActive":false},{"title":"Responsible business","url":"/en-gb/investors/responsible-business/","nodes":[],"isActive":false},{"title":"Speeches and presentations","url":"/en-gb/investors/speeches-and-presentations/","nodes":[],"isActive":false},{"title":"Science publications","url":"/en-gb/investors/science-publications/","nodes":[],"isActive":false},{"title":"Events calendar","url":"/en-gb/investors/events-calendar/","nodes":[],"isActive":false},{"title":"Dividend and share price","url":"/en-gb/investors/dividend-and-share-price/","nodes":[{"title":"GSK share price","url":"/en-gb/investors/dividend-and-share-price/gsk-share-price/","nodes":[],"isActive":false},{"title":"Share price calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calculators (GBp/USD)","url":"/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/","nodes":[],"isActive":false},{"title":"Dividend calendar","url":"/en-gb/investors/dividend-and-share-price/dividend-calendar/","nodes":[],"isActive":false}],"isActive":false},{"title":"Analyst consensus","url":"/en-gb/investors/analyst-consensus/","nodes":[],"isActive":false},{"title":"Stock exchange announcements","url":"/en-gb/investors/stock-exchange-announcements/","nodes":[{"title":"London (RNS)","url":"/en-gb/investors/stock-exchange-announcements/london-rns/","nodes":[],"isActive":false},{"title":"London (RNS) inside information","url":"/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/","nodes":[],"isActive":false},{"title":"New York (SEC)","url":"/en-gb/investors/stock-exchange-announcements/new-york-sec/","nodes":[],"isActive":false},{"title":"Sign up for announcements","url":"/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/","nodes":[],"isActive":false}],"isActive":false},{"title":"Shareholder information","url":"/en-gb/investors/shareholder-information/","nodes":[{"title":"Manage your shares","url":"/en-gb/investors/shareholder-information/manage-your-shares/","nodes":[],"isActive":false},{"title":"Annual General Meeting","url":"/en-gb/investors/shareholder-information/annual-general-meeting/","nodes":[],"isActive":false},{"title":"General Meeting","url":"/en-gb/investors/shareholder-information/general-meeting/","nodes":[],"isActive":false},{"title":"Annual Governance Meeting","url":"/en-gb/investors/shareholder-information/annual-governance-meeting/","nodes":[],"isActive":false},{"title":"Corporate sponsored nominee service","url":"/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/","nodes":[],"isActive":false},{"title":"Our ADR programme","url":"/en-gb/investors/shareholder-information/adr-programme/","nodes":[],"isActive":false},{"title":"Asset reunification - Georgeson ","url":"/en-gb/investors/shareholder-information/asset-reunification-georgeson/","nodes":[],"isActive":false},{"title":"Share scam alert","url":"/en-gb/investors/shareholder-information/share-scam-alert/","nodes":[],"isActive":false},{"title":"Privacy notice for ordinary shareholders","url":"/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/","nodes":[],"isActive":false},{"title":"FAQs","url":"/en-gb/investors/shareholder-information/shareholder-faqs/","nodes":[],"isActive":false}],"isActive":false},{"title":"Corporate actions","url":"/en-gb/investors/corporate-actions/","nodes":[{"title":"Consumer Healthcare Demerger","url":"/en-gb/investors/corporate-actions/consumer-healthcare-demerger/","nodes":[],"isActive":false},{"title":"Consumer Healthcare Joint Venture","url":"/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/","nodes":[],"isActive":false},{"title":"Agreement to acquire TESARO","url":"/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/","nodes":[],"isActive":false}],"isActive":false},{"title":"Debt investors","url":"/en-gb/investors/debt-investors/","nodes":[],"isActive":false},{"title":"Investor contacts","url":"/en-gb/investors/investor-contacts/","nodes":[],"isActive":false}],"isActive":false,"promos":[{"text":"Press releases","image":{"src":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc6f12bb0&hmac=f3dda3c7bd6599a1c2f05133bb899c647be6962b177d4b772cd87d676c8a7d94","alt":"Lab machinery","darkModeSrc":"/media/hb1dfygw/ware_3_2022_prodassmb_28_hess_nav.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc6f12bb0&hmac=39e1b2702e8059aa94f14c98a803dbe514bde3cb0ae2d3d2fd23a6e78c938b52","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/media/press-releases/","openInNewWindowText":null}},{"text":"Our pipeline","image":{"src":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=100&v=1dba2ebc701f490&hmac=bf2488fd39b58115ffca972c3b022be99778cb82fc5a894714dd3d84863ed736","alt":"Case of vials","darkModeSrc":"/media/2kyan0vw/ware_3_2022_prodqc_14_hess.jpeg?width=329&height=185&format=webp&quality=50&v=1dba2ebc701f490&hmac=31c09472f1b12264f8141bef8b943a0354c076daf5ec330cb2322259c29365b9","fileSize":""},"link":{"text":"SPOTLIGHT ON","href":"/en-gb/innovation/pipeline/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Media","url":"/en-gb/media/","nodes":[{"title":"Press releases","url":"/en-gb/media/press-releases/","nodes":[],"isActive":true},{"title":"Media contacts","url":"/en-gb/media/media-contacts/","nodes":[],"isActive":false},{"title":"Media statements","url":"/en-gb/media/media-statements/","nodes":[],"isActive":false},{"title":"Media library","url":"/en-gb/media/media-library/","nodes":[],"isActive":false},{"title":"Our social media","url":"/en-gb/media/social-media/","nodes":[],"isActive":false},{"title":"Podcasts","url":"/en-gb/media/podcasts/","nodes":[],"isActive":false},{"title":"RSS feeds","url":"/en-gb/media/rss-feeds/","nodes":[],"isActive":false}],"isActive":true,"promos":[{"text":"Behind the Science magazine","image":{"src":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebb585f130&hmac=c3e21840aa4184183d7a56b6b9e51c276f4c0cfa99faddf0b2e96abade984999","alt":"Scientist works in a futurist vaccine laboratory for GSK","darkModeSrc":"/media/ukvllwft/vaccine-manufacturing-production-line-2.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebb585f130&hmac=1ee1d1cba0cbe920daab92982b410dfd5be6b812ffb18d46bc5a1b15dc8ea9e4","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null}},{"text":"Podcasts","image":{"src":"/media/tifb3jbw/bts-podcast-cover.jpg?rxy=0.3396812535345467,0.7098154172768643&width=329&height=185&format=webp&quality=100&v=1dc8ade65132ac0&hmac=8516fcec0699f0af4c0d1d3a3cb506fb47fd5a221d6a501a81eeb2c68f1c1998","alt":"Behind the science podcast cover ","darkModeSrc":"/media/tifb3jbw/bts-podcast-cover.jpg?rxy=0.3396812535345467,0.7098154172768643&width=329&height=185&format=webp&quality=50&v=1dc8ade65132ac0&hmac=e1517c1889bf48d5e31af2d9cfabe3dfbeee773f9a250a984d718db749944c52","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/media/podcasts/","openInNewWindowText":null}}]},{"tooltip":null,"hasBorderRight":false,"title":"Careers","url":"/en-gb/careers/","nodes":[{"title":"Search jobs","url":"/en-gb/careers/search-jobs/","nodes":[],"isActive":false},{"title":"Featured careers","url":"/en-gb/careers/featured-careers/","nodes":[{"title":"A career in data","url":"/en-gb/careers/featured-careers/a-career-in-data/","nodes":[],"isActive":false}],"isActive":false},{"title":"Life at GSK","url":"/en-gb/careers/life-at-gsk/","nodes":[],"isActive":false},{"title":"Outstanding people","url":"/en-gb/careers/outstanding-people/","nodes":[{"title":"Great place to work","url":"/en-gb/careers/outstanding-people/great-place-to-work/","nodes":[],"isActive":false},{"title":"Meet our veterans","url":"/en-gb/careers/outstanding-people/meet-our-veterans/","nodes":[],"isActive":false},{"title":"Working together","url":"/en-gb/careers/outstanding-people/working-together/","nodes":[],"isActive":false},{"title":"My GSK story","url":"/en-gb/careers/outstanding-people/my-gsk-story/","nodes":[],"isActive":false},{"title":"Innovating together","url":"/en-gb/careers/outstanding-people/innovating-together/","nodes":[],"isActive":false}],"isActive":false},{"title":"Experienced professionals","url":"/en-gb/careers/experienced-professionals/","nodes":[{"title":"Business operations","url":"/en-gb/careers/experienced-professionals/business-operations/","nodes":[],"isActive":false},{"title":"Engineering at GSK ","url":"/en-gb/careers/experienced-professionals/engineering/","nodes":[],"isActive":false},{"title":"Global supply chain","url":"/en-gb/careers/experienced-professionals/global-supply-chain/","nodes":[],"isActive":false},{"title":"Sales and marketing","url":"/en-gb/careers/experienced-professionals/sales-and-marketing/","nodes":[],"isActive":false},{"title":"Research and development","url":"/en-gb/careers/experienced-professionals/research-and-development/","nodes":[{"title":"Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS)","url":"/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/","nodes":[],"isActive":false},{"title":"Genomic sciences","url":"/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/","nodes":[],"isActive":false}],"isActive":false},{"title":"Technology","url":"/en-gb/careers/experienced-professionals/technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Early careers","url":"/en-gb/careers/early-careers/","nodes":[{"title":"Application process","url":"/en-gb/careers/early-careers/application-process/","nodes":[],"isActive":false},{"title":"Apprentice programmes","url":"/en-gb/careers/early-careers/apprentice-programmes/","nodes":[],"isActive":false},{"title":"Internships and placements","url":"/en-gb/careers/early-careers/internships-and-placements/","nodes":[],"isActive":false},{"title":"Graduate programme","url":"/en-gb/careers/early-careers/graduate-programme/","nodes":[{"title":"Business operations","url":"/en-gb/careers/early-careers/graduate-programme/business-operations/","nodes":[],"isActive":false},{"title":"Engineering","url":"/en-gb/careers/early-careers/graduate-programme/engineering/","nodes":[],"isActive":false},{"title":"Manufacturing & supply","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-supply/","nodes":[],"isActive":false},{"title":"Commercial ","url":"/en-gb/careers/early-careers/graduate-programme/commercial/","nodes":[],"isActive":false},{"title":"Research & development","url":"/en-gb/careers/early-careers/graduate-programme/research-development/","nodes":[],"isActive":false},{"title":"Manufacturing sciences & technology","url":"/en-gb/careers/early-careers/graduate-programme/manufacturing-sciences-technology/","nodes":[],"isActive":false}],"isActive":false},{"title":"Post graduate opportunities","url":"/en-gb/careers/early-careers/post-graduate-opportunities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/early-careers/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false},{"title":"Veterans","url":"/en-gb/careers/veterans/","nodes":[],"isActive":false},{"title":"Our global and regional hubs","url":"/en-gb/careers/our-global-and-regional-hubs/","nodes":[],"isActive":false},{"title":"How we hire","url":"/en-gb/careers/how-we-hire/","nodes":[{"title":"Fraudulent internet recruitment activities","url":"/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/","nodes":[],"isActive":false},{"title":"Frequently asked questions","url":"/en-gb/careers/how-we-hire/frequently-asked-questions/","nodes":[],"isActive":false}],"isActive":false}],"isActive":false,"promos":[{"text":"Outstanding people","image":{"src":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=100&v=1dba2eba773f3d0&hmac=9e8e9da5bd3ca0619cfd47c6274f5ecbae61a5b73808bbd57b4fdffa469f2037","alt":"Angeles sitting on a sofa in a pink shirt","darkModeSrc":"/media/kgwp0dc5/sddefault-2.jpg?rxy=0.425,0.51807228915662651&width=329&height=185&format=webp&quality=50&v=1dba2eba773f3d0&hmac=25f6331ff89b8ea1f896e23e1cc935cee241b346efb1b08bd5aa5b5aa0d4e09c","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/careers/outstanding-people/","openInNewWindowText":null}},{"text":"Inclusion","image":{"src":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=100&v=1dba2ebc1b88030&hmac=12ac7ded8bd7ab6e4665214fcc035ed44c079abcb2fbda20ea2220be73c1f12e","alt":"Lab technician smiling","darkModeSrc":"/media/2u2dowa1/web16-header-stvg_2_2022_port_13_hess_nav.jpg?width=329&height=185&format=webp&quality=50&v=1dba2ebc1b88030&hmac=a50405e6d858c131f8bc642c26ae3a9fb06154803458a748320a0ff3ec9c7e2f","fileSize":""},"link":{"text":"Spotlight on","href":"/en-gb/responsibility/inclusion/","openInNewWindowText":null}}]}],"skipToContent":"Skip to content","skipToSearch":"Skip to search","typeaheadSearch":{"endpoint":"api/search/typeahead?siteContainerId=1703","searchFieldPlaceholderText":"Enter a search term...","searchButtonText":"Search","searchPage":"/en-gb/search/","ariaLabel":"Submit form","suggestedSearchEnabled":true,"suggestedSearchResultsEnabled":true,"suggestedSearchLabel":"Suggested search","suggestedResultsLabel":"Suggested results","noResultsText":"No results found","suggestedSearchNoResultsText":"We don't have any suggestions to your search input. Please try a different search.","resultTagColour":"#00b8ad","mostPopular":{"label":"Most popular searches","items":[{"text":"Quarterly results","url":"/en-gb/search/?q=Quarterly%20results"},{"text":"Vaccines","url":"/en-gb/search/?q=Vaccines"},{"text":"Pipeline","url":"/en-gb/search/?q=Pipeline"},{"text":"Behind the science","url":"/en-gb/search/?q=Behind%20the%20science"},{"text":"Careers","url":"/en-gb/search/?q=Careers"},{"text":"GSK at a glance","url":"/en-gb/search/?q=GSK%20at%20a%20glance"},{"text":"Podcasts","url":"/en-gb/search/?q=Podcasts"}]}},"ariaLabel":"Global navigation"},"footer":{"logo":null,"copyrightText":"

This is our global website, intended for visitors seeking information on GSK's worldwide business.  Our market sites can be reached by visiting our location selector.  

\n

 

\n

© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.

\n

GSK plc. Registered in England and Wales No. 3888792.

\n

Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG

","modernSlaveryStatement":{"name":"Modern Slavery Act Statement 2025","url":"/media/5ladhmeu/modern-slavery-act-statement-2025.pdf","fileExtension":"PDF","fileSize":"187.7KB","type":"file","target":"_blank","openInNewWindowText":"Opens in a new window"},"sections":{"socialMedia":{"columnTitle":"Follow us on:","socialMediaItems":[{"globalLink":{"text":null,"href":"http://www.linkedin.com/company/glaxosmithkline","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Linkedin","customIcon":null,"showPopupMenu":false,"type":"LinkedIn"},{"globalLink":{"text":null,"href":"http://twitter.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK X page","customIcon":null,"showPopupMenu":false,"type":"X"},{"globalLink":{"text":"Visit GSK on Bluesky","href":"https://bsky.app/profile/gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK on Bluesky","customIcon":null,"showPopupMenu":false,"type":"Bluesky"},{"globalLink":{"text":null,"href":"https://www.instagram.com/gsk/","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Instagram","customIcon":null,"showPopupMenu":false,"type":"Instagram"},{"globalLink":{"text":null,"href":"https://www.facebook.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK Facebook page","customIcon":null,"showPopupMenu":false,"type":"Facebook"},{"globalLink":{"text":null,"href":"http://www.youtube.com/GSK","target":"_blank","openInNewWindowText":"Opens in a new window"},"localLink":null,"ariaLabel":"Visit GSK YouTube Channel","customIcon":null,"showPopupMenu":false,"type":"Youtube"},{"globalLink":{"text":null,"href":"/en-gb/media/rss-feeds/","openInNewWindowText":null},"localLink":null,"ariaLabel":"Visit GSK RSS feeds","customIcon":null,"showPopupMenu":false,"type":"Rss"}]},"columns":[{"columnTitle":"GSK websites","links":[{"text":"Locations selector","href":"/en-gb/locations/","openInNewWindowText":null},{"text":"Social media directory","href":"/en-gb/media/social-media/","openInNewWindowText":null},{"text":"GSKPro for healthcare professionals","href":"https://www.gskpro.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"GSK study register","href":"https://www.gsk-studyregister.com/en/","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Supplier website","href":"https://supplier.gsk.com","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"ViiV Healthcare","href":"https://viivhealthcare.com/","target":"_blank","openInNewWindowText":"Opens in a new window"}]},{"columnTitle":"Quick links","links":[{"text":"Behind the Science magazine","href":"/en-gb/behind-the-science-magazine/","openInNewWindowText":null},{"text":"Company","href":"/en-gb/company/","openInNewWindowText":null},{"text":"Innovation","href":"/en-gb/innovation/","openInNewWindowText":null},{"text":"Products","href":"/en-gb/products/","openInNewWindowText":null},{"text":"Responsibility","href":"/en-gb/responsibility/","openInNewWindowText":null},{"text":"Investors","href":"/en-gb/investors/","openInNewWindowText":null},{"text":"Media","href":"/en-gb/media/","openInNewWindowText":null},{"text":"Careers","href":"/en-gb/careers/","openInNewWindowText":null}]},{"columnTitle":"Get in touch","links":[{"text":"Contact us","href":"/en-gb/contact-us/","openInNewWindowText":null},{"text":"Partnerships","href":"/en-gb/innovation/partnerships/","openInNewWindowText":null},{"text":"Report a possible side effect","href":"/en-gb/contact-us/report-a-possible-side-effect/","openInNewWindowText":null},{"text":"GSK Speak up","href":"https://www.gsk.com/speakup","target":"_blank","openInNewWindowText":"Opens in a new window"}]}]},"bottomLinks":[{"text":"Accessibility","href":"/en-gb/accessibility/","openInNewWindowText":null},{"text":"Digital sustainability","href":"/en-gb/digital-sustainability/","openInNewWindowText":null},{"text":"Terms of use","href":"/en-gb/terms-of-use/","openInNewWindowText":null},{"text":"Cookie policy","href":"/en-gb/cookie-policy/","openInNewWindowText":null},{"text":"Privacy notice","href":"https://privacy.gsk.com/en-gb/privacy-notice/general","target":"_blank","openInNewWindowText":"Opens in a new window"},{"text":"Sitemap","href":"/en-gb/sitemap/","openInNewWindowText":null}],"continueToLink":null,"legalApprovalText":""},"sharing":{"description":"Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.","og":[{"property":"og:title","content":"Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology"},{"property":"og:description","content":"Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology."},{"property":"og:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530&hmac=ab24aca71bcd831e94bc74c882b7abfdb757d8f146e8db21ae52c0375a0fd10d"},{"property":"og:url","content":"https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/"}],"twitter":[{"name":"twitter:card","content":"summary_large_image"},{"name":"twitter:site","content":"@gsk"},{"name":"twitter:title","content":"Results from phase III patient preference study of GSK’s Votrient® (pazopanib) vs. Sutent® (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology"},{"name":"twitter:description","content":"Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology."},{"name":"twitter:image","content":"https://www.gsk.com/media/p3clrlre/stvg_2_2022_smtlab_17_hess.jpg?width=600&format=webp&quality=100&v=1dbd496701ca530&hmac=ab24aca71bcd831e94bc74c882b7abfdb757d8f146e8db21ae52c0375a0fd10d"},{"name":"twitter:url","content":"https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology"}]},"stickyShare":null,"exitSitePreferences":{"popupEnabled":false,"title":"","texts":"","continueText":"Continue","cancelText":"Cancel","exclusionUrls":[]},"settings":{"optionalStylesheetLink":null,"themeColorHexCode":null,"headerLogoLightTheme":null,"headerLogoDarkTheme":null,"footerLogo":{"src":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=100&v=1dbf4b05a4e6470&hmac=88eee08ffc4c7e7b930ebd265a76bc829fe24564389a8e6d463f844dfe83fef8","alt":"Gsk Logo","darkModeSrc":"https://www.gsk.com/media/0jwou3xu/gsk-logo.png?width=104&format=webp&quality=50&v=1dbf4b05a4e6470&hmac=994d785e3ecfaac6bc9c67bacc48b0c287fa77e4c4f0d3de82d33bb48be5efda","fileSize":""},"scripts":[{"pageLocation":"Top","text":" \n"}],"globalWebsiteLink":null,"googleMapsApiKey":"AIzaSyA2QMg4Ww6djPKb7b9BraQn4kgJmDaLblg","textToSpeechApiKey":"70ab0a79-1d92-4286-86d2-abdd71cc785c","bingVerificationCode":"","googleAnalytics":"","siteTitle":" | GSK"},"pageSettings":{"disableBackToTopButton":false,"backToTopButtonText":"Back to top","robotsNoFollow":false,"robotsNoIndex":false,"canonicalUrl":"https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/"},"tealiumSettings":{"enabled":false,"data":""},"entryPopup":{"title":"","text":"

You are about to access GSK historic archived press release material retained as a corporate record. References to products or their uses may be out of date and not reflect current medical, safety or regulatory information. For clinical information, consult the approved national product label information (SmPC).

","continueText":"Continue","cancelText":"Cancel"},"protectedPage":false,"schema":{"jsonLdSchemas":["{\"@context\":\"https://schema.org\",\"@type\":\"NewsArticle\",\"description\":\"Data from the first patient preference study in advanced renal cell carcinoma have been published in the Journal of Clinical Oncology.\",\"mainEntityOfPage\":\"https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/\",\"author\":{\"@type\":\"Organization\",\"name\":\"GSK\",\"url\":\"https://www.gsk.com/en-gb/\"},\"datePublished\":\"2014-04-01T00:00:00+00:00\",\"headline\":\"Results from phase III patient preference study of GSK\\u2019s Votrient\\u00AE (pazopanib) vs. Sutent\\u00AE (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology\",\"keywords\":\"Medicines,Research and development\",\"articleSection\":\"Press releases\"}"]}}